The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Propanolide     oxetan-2-one

Synonyms: betapron, Betaprone, Oxetanone, Propiolactona, Propiolactone, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Propanolide


High impact information on Propanolide


Chemical compound and disease context of Propanolide


Biological context of Propanolide


Anatomical context of Propanolide

  • Although normal manufacture of HDCV involves the inactivation of the virus with beta-propiolactone (BPL), the effect of BPL on nonviral vaccine components, such as host cell components or stabilizing proteins, may be typical of the haptenic action of small molecular weight chemicals [17].
  • The FRhL-2 cell line, a diploid line derived from the lung of a fetal rhesus monkey, was used to prepare a potent rabies vaccine by adapting the Kissling strain of rabies virus to FRhL-2 cells, growing the virus in quantity, inactivating the virus with beta-propiolactone, and concentrating the virus by adsorption to aluminum phosphate [21].
  • While HAV inactivation by heat or beta-propiolactone and neutralization by specific antibodies completely abrogated hematopoietic inhibition, depletion of adherent bone marrow cells, and enrichment of progenitors did not alter the pattern of suppression, which also seemed to be independent of HuIFN-alpha, -beta, -gamma, and TNF [22].
  • Avian infectious bronchitis coronavirus (IBV) inactivated by beta-propiolactone induced partial protection of the trachea in up to 40% of chickens following one intramuscular inoculation 4 to 6 weeks prior to challenge [23].
  • Rabies virus antigen could not be detected at MEPs if the virus had been inactivated by beta propiolactone or mixed with antibody prior to injection or if the sciatic nerve had been cut 7 days earlier, similarly treated groups of mice survived for the observation period of 6 weeks [24].

Associations of Propanolide with other chemical compounds


Gene context of Propanolide

  • The direct-acting SN2 aklylating carcinogen beta-propiolactone was also administered by topical application [30].
  • The effect of beta-propiolactone treatment of deoxynucleotide templates, ribopolynucleotide templates, and the DNA polymerase from avian myeloblastosis virus was determined [31].
  • Pre-treatment of the cells for 16 h with 25 to 500 units/ml of human leucocyte interferon (Le-IF) or fibroblast interferon (F-IF) significantly reduced formation of syncytia by active virus or inactivated (u.v. or BPL) virus [32].
  • Addition of Pd(NH(3))(4)Cl(2) and NaAsO(2), which are non-genotoxic in the SOS chromotest, did not enhance the K(2)RhCl(5)- or BPL-mediated SOS sfiA induction [33].
  • The kinetics of inactivation of four different strains of HIV-1 (RF, MN, SF2 and IIIB) by beta-propiolactone (BPL) and binary ethylenimine (BEI) were studied under various conditions [34].

Analytical, diagnostic and therapeutic context of Propanolide


  1. Concentration-dependent mutation by alkylating agents in human lymphoblasts and Salmonella typhimurium: N-methyl-N-nitrosourethane and beta-propiolactone. Penman, B.W., Hoppe, H., Thilly, W.G. J. Natl. Cancer Inst. (1979) [Pubmed]
  2. Effect of combined beta-propiolactone/ultraviolet irradiation treatment on hepatitis B virus. Prince, A.M., Stephan, W. Lancet (1980) [Pubmed]
  3. Detection of different types of damage in alkylated DNA by means of human corrective endonuclease (correndonuclease). Duker, N.J., Teebor, G.W. Proc. Natl. Acad. Sci. U.S.A. (1976) [Pubmed]
  4. Quantitative assays for evaluation of HTLV-III inactivation procedures: tri(N-butyl)phosphate:sodium cholate and beta-propiolactone. Prince, A.M., Horowitz, B., Dichtelmueller, H., Stephan, W., Gallo, R.C. Cancer Res. (1985) [Pubmed]
  5. Sendai virus and herpes virus type 1 induce apoptosis in human peripheral blood mononuclear cells. Tropea, F., Troiano, L., Monti, D., Lovato, E., Malorni, W., Rainaldi, G., Mattana, P., Viscomi, G., Ingletti, M.C., Portolani, M. Exp. Cell Res. (1995) [Pubmed]
  6. Inhalation carcinogenesis of various alkylating agents. Sellakumar, A.R., Snyder, C.A., Albert, R.E. J. Natl. Cancer Inst. (1987) [Pubmed]
  7. Long-term results of aortic valve replacement with nonviable homografts. Daly, R.C., Orszulak, T.A., Schaff, H.V., McGovern, E., Wallace, R.B. Circulation (1991) [Pubmed]
  8. Mechanism of H-ras oncogene activation in mouse squamous carcinoma induced by an alkylating agent. Hochwalt, A.E., Solomon, J.J., Garte, S.J. Cancer Res. (1988) [Pubmed]
  9. Inhibition of beta-propiolactone-induced neoplasia of the forestomach and large bowel by 4-mercaptobenzene sulfonate in mice and rats. Hochalter, J.B., Wattenberg, L.W., Coccia, J.B., Galbraith, A.R. Cancer Res. (1988) [Pubmed]
  10. Inhibition of beta-propiolactone-induced mutagenesis and neoplasia by sodium thiosulfate. Wattenberg, L.W., Hochalter, J.B., Galbraith, A.R. Cancer Res. (1987) [Pubmed]
  11. Carcinogen specificity in the activation of transforming genes by direct-acting alkylating agents. Garte, S.J., Hood, A.T., Hochwalt, A.E., D'Eustachio, P., Snyder, C.A., Segal, A., Albert, R.E. Carcinogenesis (1985) [Pubmed]
  12. Inactivation of hepatitis B and non-A, non-B viruses by combined use of Tween 80, beta-propiolactone, and ultraviolet irradiation. Prince, A.M., Stephan, W., Kotitschke, R., Brotman, B. Thromb. Haemost. (1983) [Pubmed]
  13. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I. Edouard, E., Legrand, E., Astier-Gin, T., Dalibart, R., Geoffre, S., Dalbon, P., Guillemain, B., Londos-Gagliardi, D. Leukemia (1994) [Pubmed]
  14. Alterations in Bacillus subtilis transforming DNA induced by beta-propiolactone and 1,3-propane sultone, two mutagenic and carcinogenic alkylating agents. Kubinski, Z.O., Kubinski, H. J. Bacteriol. (1978) [Pubmed]
  15. Cyclophosphamide and dimethyl dioctadecyl ammonium bromide immunopotentiate the delayed-type hypersensitivity response to inactivated enveloped viruses. Smith, R.H., Ziola, B. Immunology (1986) [Pubmed]
  16. Role of depurination in mutagenesis by chemical carcinogens. Schaaper, R.M., Glickman, B.W., Loeb, L.A. Cancer Res. (1982) [Pubmed]
  17. The role of specific IgE and beta-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine. Anderson, M.C., Baer, H., Frazier, D.J., Quinnan, G.V. J. Allergy Clin. Immunol. (1987) [Pubmed]
  18. IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. Swanson, M.C., Rosanoff, E., Gurwith, M., Deitch, M., Schnurrenberger, P., Reed, C.E. J. Infect. Dis. (1987) [Pubmed]
  19. Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation--a possible new indication for high dose i.v. IgG. Greinacher, A., Liebenhoff, U., Kiefel, V., Presek, P., Mueller-Eckhardt, C. Thromb. Haemost. (1994) [Pubmed]
  20. Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. Cotten, M., Saltik, M., Kursa, M., Wagner, E., Maass, G., Birnstiel, M.L. Virology (1994) [Pubmed]
  21. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. Burgoyne, G.H., Kajiya, K.D., Brown, D.W., Mitchell, J.R. J. Infect. Dis. (1985) [Pubmed]
  22. Inhibition of in vitro hematopoiesis by hepatitis A virus. Busch, F.W., de Vos, S., Flehmig, B., Herrmann, F., Sandler, C., Vallbracht, A. Exp. Hematol. (1987) [Pubmed]
  23. Coronavirus IBV: virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection. Cavanagh, D., Davis, P.J., Darbyshire, J.H., Peters, R.W. J. Gen. Virol. (1986) [Pubmed]
  24. Entry of rabies virus into the peripheral nerves of mice. Watson, H.D., Tignor, G.H., Smith, A.L. J. Gen. Virol. (1981) [Pubmed]
  25. Neopterin radioimmunoassay results are unaffected by beta-propiolactone: safer monitoring of HIV-positive serum samples. Sheldon, J., Riches, P., Hobbs, J.R. Clin. Chem. (1990) [Pubmed]
  26. Evaluation of the effect of betapropiolactone/ultraviolet irradiation (BPL/UV) treatment of source plasma on hepatitis transmission by factor IX complex in chimpanzees. Prince, A.M., Stephan, W., Brotman, B., van den Ende, M.C. Thromb. Haemost. (1980) [Pubmed]
  27. Detection of novel non-ras oncogenes in rat nasal squamous cell carcinomas. Hochwalt, A.E., Wirgin, I., Felber, M., Currie, D.D., Garte, S.J. Mol. Carcinog. (1988) [Pubmed]
  28. Tissue-specific induction of mutations by acute oral administration of N-methyl-N'-nitro-N-nitrosoguanidine and beta-propiolactone to the Muta Mouse: preliminary data on stomach, liver and bone marrow. Brault, D., Bouilly, C., Renault, D., Thybaud, V. Mutat. Res. (1996) [Pubmed]
  29. Pyrene acts as a cocarcinogen with the carcinogens benzo[a]pyrene, beta-propiolactone and radiation in the induction of malignant transformation in cultured mouse fibroblasts; soybean extract containing the Bowman-Birk inhibitor acts as an anticarcinogen. Baturay, N., Kennedy, A.R. Cell Biol. Toxicol. (1986) [Pubmed]
  30. Induction of thymic lymphomas and squamous cell carcinomas following topic application of isopropyl methanesulfonate to female Hsd:(ICR)BR mice. Segal, A., Seidman, I., Melchionne, S. Cancer Res. (1987) [Pubmed]
  31. Restriction of carcinogen-induced error incorporation during in vitro DNA synthesis. Sirover, M.A., Loeb, L.A. Cancer Res. (1976) [Pubmed]
  32. Suppressive effects of interferon on syncytium formation by RD-114 virus in human transformed cells. Tomita, Y., Kuwata, T. J. Gen. Virol. (1979) [Pubmed]
  33. Impact of dimethyl sulfoxide and examples of combined genotoxicity in the SOS chromotest. Gebel, T., Koenig, A. Mutat. Res. (1999) [Pubmed]
  34. A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine. Race, E., Stein, C.A., Wigg, M.D., Baksh, A., Addawe, M., Frezza, P., Oxford, J.S. Vaccine (1995) [Pubmed]
  35. Characterization of a double avirulent mutant of rabies virus and its potency as a vaccine, live or inactivated. Tidke, R., Préhaud, C., Coulon, P., Blancou, J., Flamand, A. Vaccine (1987) [Pubmed]
  36. A bioassay for interferon type I based on inhibition of Sendai virus growth. Perler, L., Pfister, H., Schweizer, M., Peterhans, E., Jungi, T.W. J. Immunol. Methods (1999) [Pubmed]
  37. Vero-cell rabies vaccine produced using serum-free medium. Frazatti-Gallina, N.M., Mourão-Fuches, R.M., Paoli, R.L., Silva, M.L., Miyaki, C., Valentini, E.J., Raw, I., Higashi, H.G. Vaccine (2004) [Pubmed]
  38. A model to study the effects of a viral inactivator (beta-propiolactone) on DNA ligation and gene expression in E. coli and Cos cells. Fathallah, D.M., Zerria, K., Barbouche, M.R., Dellagi, K. Vaccine (1999) [Pubmed]
WikiGenes - Universities